Molecular basis of the selective binding of MDMA enantiomers to the alpha4beta2 nicotinic receptor subtype: Synthesis, pharmacological evaluation and mechanistic studies

European Journal of Medicinal Chemistry
2014.0

Abstract

The α4β2 nicotinic acetylcholine receptor (nAChR) is a molecular target of 3,4-methylenedioxymethamphetamine (MDMA), a synthetic drug also known as ecstasy, and it modulates the MDMA-mediated reinforcing properties. However, the enantioselective preference of the α4β2 nAChR subtype still remains unknown. Since the two enantiomers exhibit different pharmacological profiles and stereoselective metabolism, the aim of this study is to assess a possible difference in the interaction of the MDMA enantiomers with this nAChR subtype. To this end, we report a novel simple, yet highly efficient enantioselective synthesis of the MDMA enantiomers, in which the key step is the diastereoselective reduction of imides derived from optically pure tert-butylsulfinamide. The enantioselective binding to the receptor is examined using [(3)H]epibatidine in a radioligand assay. Even though the two enantiomers induced a concentration-dependent binding displacement, (S)-MDMA has an inhibition constant 13-fold higher than (R)-MDMA, which shows a Hill's coefficient not significantly different from unity, implying a competitive interaction. Furthermore, when NGF-differentiated PC12 cells were pretreated with the compounds, a significant increase in binding of [(3)H]epibatidine was found for (R)-MDMA, indicating up-regulation of heteromeric nAChR in the cell surface. Finally, docking and molecular dynamics studies have been used to identify the binding mode of the two enantiomers, which provides a structural basis to justify the differences in affinity from the differential interactions played by the substituents at the stereogenic centre of MDMA. The results provide a basis to explore the distinct psychostimulant profiles of the MDMA enantiomers mediated by the α4β2 nAChR subtype.

Knowledge Graph

Similar Paper

Molecular basis of the selective binding of MDMA enantiomers to the alpha4beta2 nicotinic receptor subtype: Synthesis, pharmacological evaluation and mechanistic studies
European Journal of Medicinal Chemistry 2014.0
Synthetic studies and pharmacological evaluations on the MDMA (‘Ecstasy’) antagonist nantenine
Bioorganic & Medicinal Chemistry Letters 2010.0
Synthesis, Pharmacology, and Biostructural Characterization of Novel α<sub>4</sub>β<sub>2</sub>Nicotinic Acetylcholine Receptor Agonists
Journal of Medicinal Chemistry 2013.0
Tying up Nicotine: New Selective Competitive Antagonist of the Neuronal Nicotinic Acetylcholine Receptors
ACS Medicinal Chemistry Letters 2015.0
Ligand Selectivity for the Acetylcholine Binding Site of the Rat α4β2 and α3β4 Nicotinic Subtypes Investigated by Molecular Docking
Journal of Medicinal Chemistry 2005.0
Synthesis, Nicotinic Acetylcholine Receptor Binding Affinities, and Molecular Modeling of Constrained Epibatidine Analogues
Journal of Medicinal Chemistry 2003.0
Conformationally restrained carbamoylcholine homologues. Synthesis, pharmacology at neuronal nicotinic acetylcholine receptors and biostructural considerations
European Journal of Medicinal Chemistry 2015.0
Effects of certain hallucinogenic amphetamine analogs on the release of [3H]-serotonin from rat brain synaptosomes
Journal of Medicinal Chemistry 1982.0
Novel methyllycaconitine analogues selective for the α4β2 over α7 nicotinic acetylcholine receptors
Bioorganic &amp; Medicinal Chemistry 2021.0
Synthesis, Binding, and Modeling Studies of New Cytisine Derivatives, as Ligands for Neuronal Nicotinic Acetylcholine Receptor Subtypes
Journal of Medicinal Chemistry 2009.0